CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that preclinical data from its Adenosine A2A receptor (A2A) and Beta-2 Adrenergic Receptor (b2AR) Agonist oncology programs demonstrated synergistic anti-cancer activity when combined with standard-of-care therapies in multiple myeloma and other B-cell malignancies. These data, which demonstrate the benefit of the CombinatoRx combination high-throughput screening technology, were presented at the American Society for Hematology (ASH) 2009 Annual Meeting in New Orleans on December 7, 2009.
